Eli Lilly disclosed Phase 2 data linking its amylin receptor agonist eloralintide to up to 20.1% mean weight loss at 48 weeks and announced plans to start Phase 3. The data showed dose‑dependent responses and a tolerability profile that the company said supports a Phase 3 launch next month. Rival data from ObesityWeek comparing amylin and GLP‑1 approaches also surfaced, with detailed cagrilsemia (CagriSema) analyses challenging proposed muscle‑sparing mechanisms for amylins and prompting a fresh round of head‑to‑head questions among developers.